Truist Securities Maintains Buy on Tenet Healthcare, Raises Price Target to $290
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst David Macdonald maintains Tenet Healthcare (NYSE:THC) with a Buy and raises the price target from $270 to $290.
Truist Securities analyst David Macdonald maintains Tenet Healthcare (NYSE:THC) with a Buy and raises the price target from $270 to $290.